ABSTRACT
Increased density of tumor-associated lymphatic vessels correlates with poor patient survival in melanoma and other cancers, yet lymphatic drainage is essential for initiating an immune response. Here we asked whether and how lymphatic vessel density (LVD) correlates with immune cell infiltration in primary tumors and lymph nodes (LNs) from patients with cutaneous melanoma. Using immunohistochemistry and quantitative image analysis, we found significant positive correlations between LVD and CD8+ T cell infiltration as well as expression of the immunosuppressive molecules inducible nitric oxide synthase (iNOS) and 2,3-dioxygénase (IDO). Interestingly, similar associations were seen in tumor-free LNs adjacent to metastatic ones, indicating loco-regional effects of tumors. Our data suggest that lymphatic vessels play multiple roles at tumor sites and LNs, promoting both T cell infiltration and adaptive immunosuppressive mechanisms. Lymph vessel associated T cell infiltration may increase immunotherapy success rates provided that the treatment overcomes adaptive immune resistance.
ABSTRACT
A sensitive and selective method of high performance liquid chromatography (HPLC) coupled to tandem mass spectrometry (MS/MS) has been developed for the simultaneous quantification of six anticancer protein kinase inhibitors (PKIs), dabrafenib, trametinib, vemurafenib, cobimetinib, pazopanib, regorafenib, and two active metabolites (regorafenib-M2 and regorafenib-M5) in human plasma. Plasma protein precipitation with methanol enables the sample extraction of 100⯵L aliquot of plasma. Analytes are detected by electrospray triple-stage quadrupole mass spectrometry and quantified using the calibration curves with stable isotope-labeled internal standards. The method was validated based on FDA recommendations, including assessment of extraction yield (74-104%), matrix effects, analytical recovery (94-104%) with low variability (<15%). The method is sensitive (lower limits of quantification within 1 to 200â¯ng/mL), accurate (intra- and inter-assay bias: -0.3% to +12.7%, and -3.2% to +6.3%, respectively) and precise (intra- and inter-assay CVs within 0.7-7.3% and 2.5-8.0%, respectively) over the clinically relevant concentration range (upper limits of quantification 500 to 100,000â¯ng/mL). This method is applied in our laboratory for both clinical research programs and routine therapeutic drug monitoring service of PKIs.
Subject(s)
Antineoplastic Agents/blood , Chromatography, High Pressure Liquid/methods , Tandem Mass Spectrometry/methods , Administration, Oral , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacokinetics , Azetidines/administration & dosage , Azetidines/blood , Azetidines/chemistry , Azetidines/pharmacokinetics , Child , Humans , Imidazoles/administration & dosage , Imidazoles/blood , Imidazoles/chemistry , Imidazoles/pharmacokinetics , Indazoles , Indoles/administration & dosage , Indoles/blood , Indoles/chemistry , Indoles/pharmacokinetics , Limit of Detection , Linear Models , Oximes/administration & dosage , Oximes/blood , Oximes/chemistry , Oximes/pharmacokinetics , Phenylurea Compounds/administration & dosage , Phenylurea Compounds/blood , Phenylurea Compounds/chemistry , Phenylurea Compounds/pharmacokinetics , Piperidines/administration & dosage , Piperidines/blood , Piperidines/chemistry , Piperidines/pharmacokinetics , Pyridines/administration & dosage , Pyridines/blood , Pyridines/chemistry , Pyridines/pharmacokinetics , Pyridones/administration & dosage , Pyridones/blood , Pyridones/chemistry , Pyridones/pharmacokinetics , Pyrimidines/administration & dosage , Pyrimidines/blood , Pyrimidines/chemistry , Pyrimidines/pharmacokinetics , Pyrimidinones/administration & dosage , Pyrimidinones/blood , Pyrimidinones/chemistry , Pyrimidinones/pharmacokinetics , Reproducibility of ResultsABSTRACT
The association of radiotherapy and immunotherapy has recently emerged as an exciting combination that might improve outcomes in many solid tumor settings. In the context of breast cancer, this opportunity is promising and under investigation. Given the heterogeneity of breast cancer, it might be meaningful to study the association of radiotherapy and immunotherapy distinctly among the various breast cancer subtypes. The use of biomarkers, such as tumor infiltrating lymphocytes, which are also associated to breast cancer heterogeneity, might provide an opportunity for tailored studies. This review highlights current knowledge of the association of radiotherapy and immunotherapy in the setting of breast cancer and attempts to highlight the therapeutic opportunities among breast cancer heterogeneity.
ABSTRACT
Purpose: Patients with cancer benefit increasingly from T-cell-based therapies, such as adoptive T-cell transfer, checkpoint blockade, or vaccination. We have previously shown that serial vaccinations with Melan-AMART-126-35 peptide, CpG-B, and incomplete Freund adjuvant (IFA) generated robust tumor-specific CD8 T-cell responses in patients with melanoma. Here, we describe the detailed kinetics of early- and long-term establishment of T-cell frequency, differentiation (into memory and effector cells), polyfunctionality, and clonotype repertoire induced by vaccination.Experimental Design: Twenty-nine patients with melanoma were treated with multiple monthly subcutaneous vaccinations consisting of CpG-B, and either the native/EAA (n = 13) or the analogue/ELA (n = 16) Melan-AMART-126-35 peptide emulsified in IFA. Phenotypes and functionality of circulating Melan-A-specific CD8 T cells were assessed directly ex vivo by multiparameter flow cytometry, and TCR clonotypes were determined ex vivo by mRNA transcript analyses of individually sorted cells.Results: Our results highlight the determining impact of the initial vaccine injections on the rapid and strong induction of differentiated effector T cells in both patient cohorts. Moreover, long-term polyfunctional effector T-cell responses were associated with expansion of stem cell-like memory T cells over time along vaccination. Dominant TCR clonotypes emerged early and persisted throughout the entire period of observation. Interestingly, one highly dominant clonotype was found shared between memory and effector subsets.Conclusions: Peptide/CpG-B/IFA vaccination induced powerful long-term T-cell responses with robust effector cells and stem cell-like memory cells. These results support the further development of CpG-B-based cancer vaccines, either alone or as specific component of combination therapies. Clin Cancer Res; 23(13); 3285-96. ©2016 AACR.
Subject(s)
Adoptive Transfer , Cancer Vaccines/immunology , MART-1 Antigen/immunology , Melanoma/therapy , Antigens, Neoplasm/immunology , Antigens, Neoplasm/therapeutic use , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/therapeutic use , Cell Differentiation/drug effects , Cell Differentiation/immunology , Freund's Adjuvant/immunology , Freund's Adjuvant/therapeutic use , HLA-A2 Antigen/immunology , Humans , Immunologic Memory/drug effects , Lipids/immunology , Lipids/therapeutic use , Lymphocyte Activation/drug effects , Lymphocyte Activation/immunology , MART-1 Antigen/therapeutic use , Melanoma/immunology , Melanoma/pathology , Stem Cells/drug effects , Stem Cells/immunology , T-Lymphocytes/immunologyABSTRACT
A major limiting factor in the success of immunotherapy is tumor infiltration by CD8+ T cells, a process that remains poorly understood. In the present study, we characterized homing receptors expressed by human melanoma-specific CD8+ T cells. Our data reveal that P-selectin binding and expression of the retention integrin, very late antigen (VLA)-1, by vaccine-induced T cells correlate with longer patient survival. Furthermore, we demonstrate that CD8+VLA-1+ tumor-infiltrating lymphocytes (TILs) are highly enriched in melanoma metastases in diverse tissues. VLA-1-expressing TIL frequently co-express CD69 and CD103, indicating tissue-resident memory T cells (TRM) differentiation. We employed a mouse model of melanoma to further characterize VLA-1-expressing TIL. Our data show that VLA-1+ TRM develop in murine tumors within 2 weeks, where they exhibit increased activation status, as well as superior effector functions. In addition, in vivo blockade of either VLA-1 or CD103 significantly impaired control of subcutaneous tumors. Together, our data indicate that VLA-1+ TRM develop in tumors and play an important role in tumor immunity, presenting novel targets for the optimization of cancer immunotherapy.
ABSTRACT
PURPOSE: Cancer vaccines aim to generate and maintain antitumor immune responses. We designed a phase I/IIa clinical trial to test a vaccine formulation composed of Montanide ISA-51 (Incomplete Freund's Adjuvant), LAG-3Ig (IMP321, a non-Toll like Receptor agonist with adjuvant properties), and five synthetic peptides derived from tumor-associated antigens (four short 9/10-mers targeting CD8 T-cells, and one longer 15-mer targeting CD4 T-cells). Primary endpoints were safety and T-cell responses. EXPERIMENTAL DESIGN: Sixteen metastatic melanoma patients received serial vaccinations. Up to nine injections were subcutaneously administered in three cycles, each with three vaccinations every 3 weeks, with 6 to 14 weeks interval between cycles. Blood samples were collected at baseline, 1-week after the third, sixth and ninth vaccination, and 6 months after the last vaccination. Circulating T-cells were monitored by tetramer staining directly ex vivo, and by combinatorial tetramer and cytokine staining on in vitro stimulated cells. RESULTS: Side effects were mild to moderate, comparable to vaccines with Montanide alone. Specific CD8 T-cell responses to at least one peptide formulated in the vaccine preparation were found in 13 of 16 patients. However, two of the four short peptides of the vaccine formulation did not elicit CD8 T-cell responses. Specific CD4 T-cell responses were found in all 16 patients. CONCLUSIONS: We conclude that vaccination with IMP321 is a promising and safe strategy for inducing sustained immune responses, encouraging further development for cancer vaccines as components of combination therapies.
Subject(s)
Antigens, CD/immunology , CD4-Positive T-Lymphocytes/immunology , CD8-Positive T-Lymphocytes/immunology , Cancer Vaccines/immunology , Melanoma/immunology , Melanoma/therapy , Peptides/immunology , Antigens, CD/chemistry , Antigens, Neoplasm/immunology , Biomarkers , CD4-Positive T-Lymphocytes/metabolism , CD8-Positive T-Lymphocytes/metabolism , Cancer Vaccines/administration & dosage , Cancer Vaccines/adverse effects , Combined Modality Therapy , Female , Humans , Lymphocyte Count , MART-1 Antigen/immunology , Male , Melanoma/pathology , Treatment Outcome , Vaccination , Lymphocyte Activation Gene 3 ProteinABSTRACT
Efficient and persisting immune memory is essential for long-term protection from infectious and malignant diseases. The yellow fever (YF) vaccine is a live attenuated virus that mediates lifelong protection, with recent studies showing that the CD8(+) T cell response is particularly robust. Yet, limited data exist regarding the long-term CD8(+) T cell response, with no studies beyond 5 years after vaccination. We investigated 41 vaccinees, spanning 0.27 to 35 years after vaccination. YF-specific CD8(+) T cells were readily detected in almost all donors (38 of 41), with frequencies decreasing with time. As previously described, effector cells dominated the response early after vaccination. We detected a population of naïve-like YF-specific CD8(+) T cells that was stably maintained for more than 25 years and was capable of self-renewal ex vivo. In-depth analyses of markers and genome-wide mRNA profiling showed that naïve-like YF-specific CD8(+) T cells in vaccinees (i) were distinct from genuine naïve cells in unvaccinated donors, (ii) resembled the recently described stem cell-like memory subset (Tscm), and (iii) among all differentiated subsets, had profiles closest to naïve cells. Our findings reveal that CD8(+) Tscm are efficiently induced by a vaccine in humans, persist for decades, and preserve a naïveness-like profile. These data support YF vaccination as an optimal mechanistic model for the study of long-lasting memory CD8(+) T cells in humans.
Subject(s)
CD8-Positive T-Lymphocytes/immunology , Immunologic Memory , Vaccination , Yellow Fever Vaccine/immunology , Yellow Fever/immunology , Adolescent , Adult , Aged , Antigens, Viral/immunology , Cell Proliferation , Epitopes/immunology , Gene Expression Profiling , Homeostasis , Humans , Interleukin-15/metabolism , Lymphocyte Subsets/immunology , Middle Aged , Peptides/immunology , Phenotype , RNA, Messenger/genetics , RNA, Messenger/metabolism , Yellow Fever/genetics , Yellow Fever/virology , Young AdultABSTRACT
Autoimmune side effects are frequent in patients with cancer treated with immune checkpoint-targeting antibodies, but are rare with cancer vaccines. Here, we present a case report on a patient with metastatic melanoma who developed pulmonary sarcoid-like granulomatosis following repetitive vaccinations with peptides and CpG. Despite multiple metastases, including one lesion in the brain, the patient is alive and well more than 13 years after the diagnosis of metastatic disease. The strongly activated tumor-specific CD8(+) T cells showed robust long-term memory and effector functions. It is possible that long-term survival and adverse autoimmune events may become more common for vaccines inducing robust anticancer immune responses as were present in this patient.
Subject(s)
Lymphomatoid Granulomatosis/etiology , Melanoma/complications , Melanoma/immunology , Sarcoidosis, Pulmonary/etiology , Adult , Antigens, Neoplasm/immunology , Antigens, Neoplasm/metabolism , Autoimmunity , Brain Neoplasms/diagnosis , Brain Neoplasms/secondary , Cancer Vaccines/administration & dosage , Cancer Vaccines/adverse effects , Humans , Immunohistochemistry , Lymphocytes, Tumor-Infiltrating/immunology , Lymphocytes, Tumor-Infiltrating/metabolism , Lymphomatoid Granulomatosis/diagnosis , Magnetic Resonance Imaging , Male , Melanoma/diagnosis , Melanoma/therapy , Neoplasm Metastasis , Positron-Emission Tomography , Sarcoidosis, Pulmonary/diagnosis , Tomography, X-Ray ComputedABSTRACT
Metastatic melanoma has a poor prognosis with high resistance to chemotherapy and radiation. Recently, the anti-CTLA-4 antibody ipilimumab has demonstrated clinical efficacy, being the first agent to significantly prolong the overall survival of inoperable stage III/IV melanoma patients. A major aim of patient immune monitoring is the identification of biomarkers that predict clinical outcome. We studied circulating myeloid-derived suppressor cells (MDSC) in ipilimumab-treated patients to detect alterations in the myeloid cell compartment and possible correlations with clinical outcome. Lin(-) CD14(+) HLA-DR(-) monocytic MDSC were enriched in peripheral blood of melanoma patients compared to healthy donors (HD). Tumor resection did not significantly alter MDSC frequencies. During ipilimumab treatment, MDSC frequencies did not change significantly compared to baseline levels. We observed high inter-patient differences. MDSC frequencies in ipilimumab-treated patients were independent of baseline serum lactate dehydrogenase levels but tended to increase in patients with severe metastatic disease (M1c) compared to patients with metastases in skin or lymph nodes only (M1a), who had frequencies comparable to HD. Interestingly, clinical responders to ipilimumab therapy showed significantly less lin(-) CD14(+) HLA-DR(-) cells as compared to non-responders. The data suggest that the frequency of monocytic MDSC may be used as predictive marker of response, as low frequencies identify patients more likely benefitting from ipilimumab treatment. Prospective clinical trials assessing MDSC frequencies as potential biomarkers are warranted to validate these observations.
Subject(s)
Antibodies, Monoclonal/administration & dosage , Melanoma/drug therapy , Myeloid Cells/drug effects , Skin Neoplasms/drug therapy , Adult , Aged , Aged, 80 and over , Biomarkers, Pharmacological , Cell Count , Female , Humans , Immune Tolerance , Ipilimumab , Lipopolysaccharide Receptors/metabolism , Male , Melanoma/blood , Middle Aged , Myeloid Cells/immunology , Neoplasm Metastasis , Neoplasm Staging , Skin Neoplasms/blood , Treatment Outcome , Young AdultABSTRACT
Pyrazolo-pyrido-diazepine, -pyrazine and -oxazine dione derivatives are new chemical entities with good and attractive druglikeness properties. A series of pyrazolo-pyrido-diazepine dione analogs demonstrated to be particularly amenable to lead optimization through a couple of cycles in order to improve specificity for isoforms Nox4 and Nox1 and had excellent pharmacokinetic parameters by oral route. Several molecules such as compound 7c proved to be highly potent in in vitro assays on human lung fibroblasts differentiation as well as in curative murine models of bleomycin-induced pulmonary fibrosis with superior efficiency over Pirfenidone. Pyrazolo-pyrido-diazepine dione derivatives targeting Nox4 and Nox1 isoforms appear highly promising therapeutics for the treatment of idiopathic pulmonary fibrosis.
Subject(s)
Azepines/chemistry , Enzyme Inhibitors/chemistry , NADPH Oxidases/antagonists & inhibitors , Oxazines/chemistry , Pyrazines/chemistry , Administration, Oral , Animals , Azepines/chemical synthesis , Azepines/pharmacology , Bleomycin/toxicity , Disease Models, Animal , Enzyme Inhibitors/chemical synthesis , Enzyme Inhibitors/pharmacology , Humans , Male , Mice , Mice, Inbred C57BL , NADPH Oxidase 1 , NADPH Oxidase 4 , Oxazines/chemical synthesis , Oxazines/pharmacology , Pulmonary Fibrosis/chemically induced , Pulmonary Fibrosis/drug therapy , Pyrazines/chemical synthesis , Pyrazines/pharmacology , Pyridones/pharmacology , Structure-Activity RelationshipABSTRACT
Neuroinflammation is observed in many brain pathologies: in neurodegenerative diseases and multiple sclerosis as well as in chemically induced lesions. It is characterized by the reactivity of microglial cells and astrocytes, activation of inducible NO-synthase (i-NOS), and increased expression and/or release of cytokines and chemokines. Clearly, cell-to-cell signaling between the different brain cell types plays an important role in the initiation and propagation of neuroinflammation, but despite the growing list of known molecular actors, the underlying pathways and the sequence of events remain to be fully elucidated. The present chapter presents an example of how to assess neuroinflammation in complex brain tissues, using aggregating brain cell cultures as an in vitro model. This three-dimensional cell culture system provides optimal cell-to-cell interactions crucial for histotypic cellular maturation and control of neuroinflammatory processes. The techniques described here comprise immunocytochemistry to assess the reactivity of microglia and astrocytes and the expression of cytokines; quantitative RT-PCR to measure the mRNA expression of cytokines (TNF-α, IL-1ß, IL-6, IL-1ra, TGF-ß, IL-15, IFN-γ), chemokines (ccl5, cxcl1, cxcl2), and i-NOS; and immunoblotting to assess MAP kinase pathway activation (phosphorylation of p38 and p44/42 MAP kinases).
Subject(s)
Astrocytes/immunology , Cell Culture Techniques/methods , Cytokines/biosynthesis , Encephalitis/immunology , Microglia/immunology , Animals , Astrocytes/cytology , Astrocytes/metabolism , Biomarkers/analysis , Cytokines/genetics , Cytokines/immunology , Encephalitis/metabolism , Encephalitis/pathology , Humans , Immunoblotting , Immunohistochemistry , Microglia/cytology , Microglia/metabolism , Mitogen-Activated Protein Kinases/metabolism , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
We describe the design, synthesis, and optimization of first-in-class series of inhibitors of NADPH oxidase isoform 4 (Nox4), an enzyme implicated in several pathologies, in particular idiopathic pulmonary fibrosis, a life-threatening and orphan disease. Initially, several moderately potent pyrazolopyridine dione derivatives were found during a high-throughput screening campaign. SAR investigation around the pyrazolopyridine dione core led to the discovery of several double-digit nanomolar inhibitors in cell free assays of reactive oxygen species (ROS) production, showing high potency on Nox4 and Nox1. The compounds have little affinity for Nox2 isoform and are selective for Nox4/1 isoforms. The specificity of these compounds was confirmed in an extensive in vitro pharmacological profile, as well as in a counterscreening assay for potential ROS scavenging. Concomitant benefits are good oral bioavailability and high plasma concentrations in vivo, allowing further clinical trials for the potential treatment of fibrotic diseases, cancers, and cardiovascular and metabolic diseases.
Subject(s)
NADPH Oxidases/antagonists & inhibitors , Pulmonary Fibrosis/drug therapy , Pyrazoles/chemical synthesis , Pyridines/chemical synthesis , Administration, Oral , Animals , Biological Availability , Cell Line , Chronic Disease , Cricetinae , Cricetulus , Free Radical Scavengers/chemical synthesis , Free Radical Scavengers/chemistry , Free Radical Scavengers/pharmacology , High-Throughput Screening Assays , Humans , Isoenzymes/antagonists & inhibitors , Kidney Diseases/drug therapy , Male , Microsomes, Liver/metabolism , NADPH Oxidase 4 , Pyrazoles/chemistry , Pyrazoles/pharmacology , Pyridines/chemistry , Pyridines/pharmacology , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Structure-Activity RelationshipABSTRACT
In pediatric patients, hyperammonemia can provoke irreversible damages to developing CNS like cortical atrophy, ventricular enlargement, demyelination or gray and white matter hypodensities which are concordant with alterations of neurons and oligodendrocytes. Cerebral injury triggers endogenous protective mechanisms that can prevent or limit brain damage. Understanding these mechanisms may lead to new therapeutic strategies. We investigated whether ciliary neurotrophic factor (CNTF), a cytokine-like protein expressed by astrocytes and described as an injury-associated survival factor, was up-regulated by ammonia in developing reaggregated 3D brain cell cultures. We showed that CNTF is up-regulated by ammonia exposure, through mediation of p38 MAPK activation in astrocytes. We also observed that SAPK/JNK and Erk1/2 activations in oligodendrocytes and neurons, respectively, also play indirect roles in CNTF synthesis by astrocytes. Co-treatment with exogenous CNTF demonstrated strong protective effects on oligodendrocytes, but not on neurons, against ammonia toxicity. These protective effects involved JAK/STAT, SAPK/JNK and c-jun proteins.
Subject(s)
Ammonia/toxicity , Astrocytes/metabolism , Ciliary Neurotrophic Factor/metabolism , MAP Kinase Signaling System , Neurons/metabolism , Oligodendroglia/metabolism , Animals , Brain/cytology , Brain/metabolism , Cell Survival/physiology , Cells, Cultured , Ciliary Neurotrophic Factor Receptor alpha Subunit/metabolism , Coculture Techniques , Janus Kinases/metabolism , MAP Kinase Kinase 4/metabolism , Mitogen-Activated Protein Kinase 1/metabolism , Mitogen-Activated Protein Kinase 3/metabolism , Oligodendroglia/drug effects , Proto-Oncogene Proteins c-jun/metabolism , Rats , Rats, Sprague-Dawley , STAT Transcription Factors/metabolism , p38 Mitogen-Activated Protein Kinases/metabolismABSTRACT
Hyperammonemia in neonates and infants causes irreversible damages in the developing CNS due to brain cell loss. Elucidating the mechanisms triggering ammonia-induced cell death in CNS is necessary for the development of neuroprotective strategies. We used reaggregated developing brain cell cultures derived from fetal rat telencephalon exposed to ammonia as an experimental model. Ammonia induced neuronal and oligodendroglial death, triggered apoptosis and activated caspases and calpain. Probably due to calpain activation, ammonia caused the cleavage of the cyclin-dependent kinase 5 activator, p35, to p25, the cdk5/p25 complex being known to lead to neurodegeneration. Roscovitine, a cdk5 inhibitor, protected neurons from ammonia-induced cell death. However, roscovitine also impaired axonal growth, probably through inhibition of the remaining cdk5/p35 activity, which is involved in neurite outgrowth. Thus, cdk5 appears as a promising therapeutic target for treating hyperammonemic newborns and infants, especially if one develops specific cdk5/p25 inhibitors.
Subject(s)
Ammonia/pharmacology , Calpain/metabolism , Caspases/metabolism , Cyclin-Dependent Kinase 5/metabolism , Neurons/drug effects , Prosencephalon/cytology , Animals , Cell Death/drug effects , Cells, Cultured , Dose-Response Relationship, Drug , Embryo, Mammalian , Enzyme Inhibitors/pharmacology , Immunoprecipitation/methods , L-Lactate Dehydrogenase/metabolism , Molecular Weight , Nerve Tissue Proteins/metabolism , Neurons/enzymology , Rats , Rats, Sprague-Dawley , Time FactorsABSTRACT
Hyperammonemic disorders in pediatric patients lead to poorly understood irreversible effects on the developing brain that may be life-threatening. We showed previously that some of these NH4+-induced irreversible effects might be due to impairment of axonal growth that can be protected under ammonium exposure by creatine co-treatment. The aim of the present work was thus to analyse how the genes of arginine:glycine amidinotransferase (AGAT) and guanidinoacetate methyltransferase (GAMT), allowing creatine synthesis, as well as of the creatine transporter SLC6A8, allowing creatine uptake into cells, are regulated in rat brain cells under NH4+ exposure. Reaggregated brain cell three-dimensional cultures exposed to NH4Cl were used as an experimental model of hyperammonemia in the developing central nervous system (CNS). We show here that NH4+ exposure differentially alters AGAT, GAMT and SLC6A8 regulation, in terms of both gene expression and protein activity, in a cell type-specific manner. In particular, we demonstrate that NH4+ exposure decreases both creatine and its synthesis intermediate, guanidinoacetate, in brain cells, probably through the inhibition of AGAT enzymatic activity. Our work also suggests that oligodendrocytes are major actors in the brain in terms of creatine synthesis, trafficking and uptake, which might be affected by hyperammonemia. Finally, we show that NH4+ exposure induces SLC6A8 in astrocytes. This suggests that hyperammonemia increases blood-brain barrier permeability for creatine. This is normally limited due to the absence of SLC6A8 from the astrocyte feet lining microcapillary endothelial cells, and thus creatine supplementation may protect the developing CNS of hyperammonemic patients.
Subject(s)
Brain/metabolism , Creatine/biosynthesis , Creatine/deficiency , Membrane Transport Proteins/metabolism , Quaternary Ammonium Compounds/toxicity , Animals , Biological Transport/drug effects , Biological Transport/physiology , Brain/cytology , Brain/embryology , Cell Culture Techniques/methods , Cells, Cultured , Creatine/genetics , Female , Membrane Transport Proteins/biosynthesis , Membrane Transport Proteins/genetics , Pregnancy , RatsABSTRACT
In pediatric patients, hyperammonemia can be caused by various acquired or inherited disorders such as urea cycle deficiencies or organic acidemias. The brain is much more susceptible to the deleterious effects of ammonium during development than in adulthood. Hyperammonemia can provoke irreversible damages to the developing central nervous system that lead to cortical atrophy, ventricular enlargement and demyelination, responsible for cognitive impairment, seizures and cerebral palsy. Until recently, the mechanisms leading to these irreversible cerebral damages were poorly understood. Using experimental models allowing the analysis of the neurotoxic effects of ammonium on the developing brain, these last years have seen the emergence of new clues showing that ammonium exposure alters several amino acid pathways and neurotransmitter systems, as well as cerebral energy metabolism, nitric oxide synthesis, oxidative stress, mitochondrial permeability transition and signal transduction pathways. Those alterations may explain neuronal loss and impairment of axonal and dendritic growth observed in the different models of congenital hyperammonemia. Some neuroprotective strategies such as the potential use of NMDA receptor antagonists, nitric oxide inhibitors, creatine and acetyl-l-carnitine have been suggested to counteract these toxic effects. Unraveling the molecular mechanisms involved in the chain of events leading to neuronal dysfunction under hyperammonemia may be useful to develop new potential strategies for neuroprotection.
Subject(s)
Brain Diseases, Metabolic, Inborn/physiopathology , Brain/growth & development , Brain/physiopathology , Hyperammonemia/complications , Hyperammonemia/physiopathology , Ammonia/metabolism , Animals , Brain/metabolism , Brain Diseases, Metabolic, Inborn/metabolism , Cerebral Palsy/etiology , Cerebral Palsy/metabolism , Cerebral Palsy/physiopathology , Child , Energy Metabolism/physiology , Humans , Hyperammonemia/metabolism , Intellectual Disability/etiology , Intellectual Disability/metabolism , Intellectual Disability/physiopathology , Nerve Degeneration/etiology , Nerve Degeneration/metabolism , Nerve Degeneration/physiopathology , Rett Syndrome/metabolism , Rett Syndrome/physiopathologyABSTRACT
BACKGROUND: Peptidergic neurons containing the melanin-concentrating hormone (MCH) and the hypocretins (or orexins) are intermingled in the zona incerta, perifornical nucleus and lateral hypothalamic area. Both types of neurons have been implicated in the integrated regulation of energy homeostasis and body weight. Hypocretin neurons have also been involved in sleep-wake regulation and narcolepsy. We therefore sought to determine whether hypocretin and MCH neurons express Fos in association with enhanced paradoxical sleep (PS or REM sleep) during the rebound following PS deprivation. Next, we compared the effect of MCH and NaCl intracerebroventricular (ICV) administrations on sleep stage quantities to further determine whether MCH neurons play an active role in PS regulation. RESULTS: Here we show that the MCH but not the hypocretin neurons are strongly active during PS, evidenced through combined hypocretin, MCH, and Fos immunostainings in three groups of rats (PS Control, PS Deprived and PS Recovery rats). Further, we show that ICV administration of MCH induces a dose-dependent increase in PS (up to 200%) and slow wave sleep (up to 70%) quantities. CONCLUSION: These results indicate that MCH is a powerful hypnogenic factor. MCH neurons might play a key role in the state of PS via their widespread projections in the central nervous system.